Fig. 2
From: Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
ZMC1 reactivates p53R172H in BRCA1-deficient cell lines derived from genetically engineered mouse models. a Mice breeding scheme. b ZMC1 sensitivity of cell lines derived from Brca1−/−;Trp53−/− and Brca1−/− Trp53R172H/− mouse breast tumors. (n = 4) c Immunofluorecence staining of the mutant p53R172H protein in Brca1−/− Trp53R172H/− cells after 1 μM ZMC1 treatment for 6 h using PAB240 and CM5 antibodies. d Western blotting showed p-Chk1, p53, p21, and CC3 protein levels in Brca1−/−;Trp53R172H/− cells after ZMC1 treatment. e Annexin V/PI staining showed the increase of apoptotic cells in Brca1−/−;Trp53−/− and Brca1−/−;Trp53R172H/− cells after 1 µM ZMC1 treatment for 24 h. Student t-test; ***p < 0.001. (n = 3) f β-galactosidase staining in Brca1−/−;Trp53R172H/− cells after 0.5 μM ZMC1 treatment for 3 days. n.s.: not significant. (n = 5)
